APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy

Frontiers in Bioscience

Volumn 11, Issue 2 P.1199-1590, 2006, Pages 1549-1568

  Bucur, Octavian ^a,b   Ray, Subrata ^a   Bucur, Maria Cristina ^b   Almasan, Alexandra ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apo2L; Apoptosis; Cell Death; Cytokine; Prostate; Review; TNF; TRAIL

Indexed keywords

EID: 32844455274     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1903     Document Type: Review

References (162)

1. Almasan A., and A. Ashkenazi: Apo2L/TRAIL: apoposis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14, 337-48 (2003)
2. Pan G., K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni and V.M. Dixit: The receptor for the cytotoxic ligand TRAIL. Science 276, 111-3 (1997)
3. Wu G.S., T.F. Burns, E.R. McDonald 3rd, W. Jiang, R. Meng, I.D. Krantz, G. Kao, D.D. Gan, J.Y. Zhou, R. Muschel, S.R. Hamilton, N.B. Spinner, S. Markowitz, G. Wu G and W.S. El-Deiry: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17, 141-3 (1997)
4. Sheridan J.P., S.A. Marsters, R.M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C.L. Gray, K. Baker, W.I. Wood, A.D. Goddard, P. Godowski and A. Ashkenazi: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-21 (1997)
5. Marsters S.A., J.P. Sheridan, R.M. Pitti, A. Huang, M. Skubatch, D. Baldwin, J. Yuan, A. Gurney, A.D. Goddard, P. Godowski and A. Ashkenazi: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7, 1003-6 (1997)
6. Emery J.G., P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, C. Silverman, E. Dul, E.R. Appelbaum, C. Eichman, R. DiPrinzio, R.A. Dodds, I.E. James, M. Rosenberg, J.C. Lee and P.R. Young: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273, 14363-7 (1998)
7. Gong B. and A. Almasan: Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 278, 747-52 (2000)
8. Chen Q., B. Gong, A. S. Mahmoud-Ahmed, A. Zhou, E. D. Hsi, M. Hussein and A. Almasan: Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98(7), 2183-92 (2001)
9. Baetu T.M., H. Kwon, S. Sharma, N. Grandvaux and J. Hiscott: Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 167, 3164-73 (2001)
10. Matsuda T., A. Almasan, M. Tomita, J.N. Uchihara, M. Masuda, K. Ohshiro, N. Takasu, H. Yagita, T. Ohta and N. Mori: Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. J Virol 79, 1367-78 (2005)
11. Matsuda T., A. Almasan, M. Tomita, K. Tamaki, M. Saito, M. Tadano, H. Yagita, T. Ohta and N. Mori: Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand. J Gen Virol 86, 1055-65 (2005)
12. Clarke N., A.M. Jimenez-Lara, E. Voltz and H. Gronemeyer: Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO Journal 23, 3051-3060 (2004)
13. Kirshner J. R., A.Y. Karpova, M. Kops and P.M. Howley: Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virology 79, 9320-4 (2005)
14. Modur V., R. Nagarajan, B.M. Evers and J. Milbrandt: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277, 47928-37 (2002)
15. Ghaffari S., Z. Jagani, C. Kitidis, H. F. Lodish and R. Khosravi-Far: Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. PNAS 100, 6523-6528 (2003)
16. Ray S., J. Hissong, M. Oancea and A. Almasan: Expression and regulation of death receptors in multiple myeloma and prostate carcinoma. In: Death Receptors in Cancer Therapy. Ed: W. El-Deiry, Humana Press, 281-296 (2004)
17. Shivapurkar N., S. Toyooka, K. O. Toyooka, J. Reddy, K. Miyajima, M. Suzuki, H. Shigematsu, T. Takahashi, G. Parikh, H.I. Pass, P.M. Chaudhary and A.F. Gazdar: Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109, 786-92 (2004)
18. Kischkel F. C., S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. H. Krammer and M.E. Peter: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO Journal 14, 5579-88 (1995)
19. Kischkel F. C., D. A. Lawrence, A. Chuntharapai, P. Schow, K. J. Kim and A. Ashkenazi: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-20 (2000)
20. Kischkel, F.C., D.A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott, A. Ashkenazi: Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276, 46639-46646 (2001)
21. Danial N. N. and S. J. Korsmeyer: Cell death: critical control points. Cell 116, 205-219 (2004)
22. Lazebnik Y. A., S. H. Kaufmann, S. Desnoyers, G. G. Poirier and W.C. Earnshaw: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371, 346-347 (1994)
23. Sheikh M. S., T. F. Burns, Y. Huang, G. S. Wu, S. Amundson, K. S. Brooks, A. J. Fornace Jr and W. S. el-Deiry: p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58, 1593-8 (1998)
24. Green D. R. and G. Kroemer: The Pathophysiology of Mitochondrial Cell Death. Science 305, 626-629 (2004)
25. Philchenkov A.: Caspases: potential targets for regulating cell death. J Cell Mol Med 8, 432-44 (2004)
26. Zou H., Y. Li, X. Liu and X. Wang: An APAF-1, cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274, 11549-56 (1999)
27. Srinivasula S. M., M. Ahmad, T. Fernandes-Alnemri and E. S. Alnemri: Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1, 949-957 (1998)
28. Scaffidi C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K. M. Debatin, P.H. Krammer and M. E. Peter: Two CD95 (APO-1/Fas) signaling pathways. EMBO Journal 17, 1675-87 (1998)
29. Jin Z. and W.S. El-Deiry: Overview of cell death signaling pathways. Cancer Biol Ther 4, 139-63 (2005)
30. Bucur O., R. Nat, D. Cretoiu and L. M. Popescu: Phagocytosis of apoptotic cells by microglia in vitro. J Cell Mol Med 5, 438-41 (2001)
31. Rokhlin O. W., N. V. Guseva, A. F. Tagiyev, R. A. Glover and M. B. Cohen: Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 52, 1-11 (2002)
32. Yu R., S. Mandlekar, S. Ruben, J. Ni and A. N. Kong: Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 60, 2384-9 (2000)
33. Shankar S., X. Chen and R.K. Srivastava: Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62, 165-86 (2005)
34. Tong X. and H. Li: eNOS protects prostate cancer cells from TRAIL-induced apoptosis. Cancer Lett 210(1), 63-71 (2004)
35. Nesterov A., Y. Ivashchenko and A. S. Kraft: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21, 1135-40 (2002)
36. Ray S. and A. Almasan: Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 63, 4713-23 (2003)
37. von Haefen C., B. Gillissen, P. G. Hemmati, J. Wendt, D. Guner, A. Mrozek, C. Belka, B. Dorken and P. T. Daniel: Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23, 8320-32 (2004)
38. LeBlanc, H., D. Lawrence, E. Varfolomeev, K. Totpal, J. Morlan, P. Schow, S. Fong, R. Schwall, D. Sinicropi, A. Ashkenazi: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8, 274-281 (2002)
39. Sonnemann J., V. Gekeler, A. Sagrauske, C. Muller, H. P. Hofmann and J. F. Beck: Apoptotic responsiveness of PC-3 prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand: evidence for differential effects of Bcl-xL and Bcl-2 down-regulation. Int J Oncol 25, 1171-81 (2004)
40. Franco A. V., X. D. Zhang, E. Van Berkel, J. E. Sanders, X. Y. Zhang, W. D. Thomas, T. Nguyen and P. Hersey: The role of NF-kB in TNFrelated apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166, 5337-45 (2001)
41. Beg A. A. and D. Baltimore: An essential role for NF-kappaB in preventing TNF-induced cell death. Science 274, 782-4 (1996)
42. Deeb D., H. Jiang, X. Gao, M. S. Hafher, H. Wong, G. Divine, R. A. Chapman, S. A. Dulchavsky and S. C. Gautam: Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 3, 803-12 (2004)
43. Eid M. A., R. W. Lewis, A. B. Abdel-Mageed and M. V. Kumar: Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation. Int J Oncol 21, 111-7 (2002)
44. An J., Y. P. Sun, J. Adams, M. Fisher, A. Belldegrun and M. B. Rettig: Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 9, 4537-45 (2003)
45. Guseva N. V., A. F. Taghiyev, M. T. Sturm, O. W. Rokhlin and M. B. Cohen: Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines. Mol Cancer Res 2, 574-84 (2004)
46. Kemp T. J., J. S. Kim, S. A. Crist and T. S. Griffith: Induction of necrotic tumor cell death by TRAIL/Apo-2L. Apoptosis 8, 587-99 (2003)
47. Mills K. R., M. Reginato, J. Debnath, B. Queenan and J. S. Brugge: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci U S A 101, 3438-43 (2004)
48. Lum, J.J., D.E. Bauer, M. Kong, M.H. Harris, C. Li, T. Lindsten, C.B. Thompson: Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120, 237-248 (2005)
49. Bunz F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler and B. Vogelstein: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501 (1998)
50. Andreassen P. R., F. B. Lacroix, O. D. Lohez and R. L. Margolis: Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells. Cancer Res 61, 7660-7668 (2001)
51. Roninson I. B., E. V. Broude and B. D. Chang: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Update 4, 303-313 (2001)
52. Huang X., T. Tran, L. Zhang, R. Hatcher and P. Zhang: DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc Natl Acad Sci U S A 102, 1065-70 (2005)
53. Pitti R. M., S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore and A. Ashkenazi: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271, 12687-90 (1996)
54. Walczak H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. Schuh and D. H. Lynch: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5, 157-63 (1999)
55. Gong B. and A. Almasan: Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res 60, 5754-60 (2000)
56. Lawrence D., Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, B. Mounho, K. Hillan, K. Totpal, L. DeForge, P. Schow, J. Hooley, S. Sherwood, R. Pai, S. Leung, L. Khan, B. Gliniak, J. Bussiere, C. A. Smith, S. S. Strom, S. Kelley, J. A. Fox, D. Thomas and A. Ashkenazi: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7(4), 383-5 (2001)
57. Ashkenazi A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh and R. H. Schwall: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104, 155-62 (1999)
58. Chuntharapai A., K. Dodge, K. Grimmer, K. Schroeder, S. A. Marsters, H. Koeppen, A. Ashkenazi and K. J. Kim: Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166, 4891-8 (2001)
59. Ichikawa K., W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J. D. Mountz, W. J. Koopman, R. P. Kimberly, T. Zhou: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7, 954-60 (2001)
60. Sobel R. E. and M. D. Sadar: Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J Urol 173, 342-59 (2005)
61. Sobel R. E., M. D. Sadar: Cell lines used in prostate cancer research: a compendium of old and new lines-part 2. J Urol 173, 360-72 (2005)
62. Stone K. R., D. D. Mickey, H. Wunderli, G. H. Mickey and D. E. Paulson: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21, 274-281 (1978)
63. Billstrom A., I. Lecander, F. Dagnaes-Hansen, B. Dahllof, U. Stenram and B. Hartley-Asp: Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft. Prostate 26, 94-104 (1995)
64. Sherwood E. R., L. A. Berg, N. J. Mitchell, J. E. McNeal, J. M. Kozlowski and C. Lee: Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol 143, 167-71 (1990)
65. Mickey D. D., K. R. Stone, H. Wunderli, G. H. Mickey, R. T. Vollmer and D. F. Paulson: Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res 37, 4049-58 (1977)
66. Nesterov A., X. Lu, M. Johnson, G. J. Miller, Y. Ivashchenko, A. S. Kraft: Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276, 10767-74 (2001)
67. Chen X., H. Thakkar, F. Tyan, S. Gim, H. Robinson, C. Lee, S. K. Pandey, C. Nwokorie, N. Onwudiwe and R. K. Srivastava: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20, 6073-83 (2001)
68. Nimmanapalli R., C. L. Perkins, M. Orlando, E. O'Bryan, D. Nguyen and K. N. Bhalla: Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61, 759-63 (2001)
69. Voelkel-Johnson C., D. L. King and J. S. Norris: Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 9, 164-72 (2002)
70. Wang, Y., J.G. Corr, H.T. Thaler, Y. Tao, W.R. Fair, W.D. Heston: Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 87, 1456-1462 (1995)
71. Horoszewicz J. S., S. S. Leong, E. Kawinski, J. P. Karr, H. Rosenthal, T. M. Chu, E. A. Mirand and G. P. Murphy: LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-18 (1983)
72. Veldscholte J. C. Ris-Stalpers, G. G. Kuiper, G. Jenster, C. Berrevoets, E. Claassen, H. C. van Rooij, J. Trapman, A. O. Brinkmann and E. Mulder: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990)
73. van Bokhoven A. A. Caires, M. D. Maria, A. P. Schulte, M. S. Lucia, S. K. Nordeen, G. J. Miller and M. Varella-Garcia: Molecular characterization of human prostate carcinoma cell lines. Prostate 57, 226-44 (2003)
74. Zhang X., T. G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far and A. F. Olumi: Persistent c-FLIPL expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64, 7086-91 (2004)
75. Wu H. C, J. T. Hsieh, M. E. Gleave, N. M. Brown, S. Pathak and L. W. Chung: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57(3), 406-12, (1994)
76. Thalmann G. N., P. E. Anezinis, S. M. Chang, H. E. Zhau, E. E. Kim, V. L. Hopwood, S. Pathak, A. C. von Eschenbach, L. W. Chung: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54, 2577-81 (1994)
77. Kaighn M. E., K. S. Narayan, Y. Ohnuki, J. F. Lechner and L. W. Jones: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17, 16-23 (1979)
78. Webber M., D. Bello and S. Quader: Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. III. Oncogenes, suppressor genes, and applications. Prostate 30, 136-142, (1997)
79. Sherwood E. R., L. A. Berg, N. J. Mitchell, J. E. McNeal, J. M. Kozlowski and C. Lee: Differential cytokeratin expres-sion in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol 143, 167-71 (1990)
80. Loop S. M., T. A. Rozanski and R. C. Ostenson: Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate 22, 93-108 (1993)
81. Pan Y., W. O. Lui, N. Nupponen N., C. Larsson, J. Isola, T. Visakorpi, U. S. Bergerheim and S. Kytola: 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. Genes Chromosomes Cancer 30, 187-95 (2001)
82. Brothman A. R., L. J. Lesho, K. D. Somers, G. L. Wright Jr. and D. J. Merchant: Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma. Int J Cancer 44(5), 898-903 (1989)
83. Varella-Garcia M., T. Boomer and G. J. Miller: Karyotypic similarity identified by multiplex-FISH relates four prostate adenocarcinoma cell lines: PC-3, PPC-1, ALVA-31, and ALVA-41. Genes Chromosomes Cancer 31, 303-15, (2001)
84. van Bokhoven A., M. Varella-Garcia, C. Korch, D. Hessels and G. J. Miller: Widely used prostate carcinoma cell lines share common origins. Prostate 47(1), 36-51 (2001)
85. Chen T. R.: Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. Cytogenet Cell Genet 62, 183-4, (1993)
86. Brothman A. R., P. C. Wilkins, E. W. Sales and K. D. Somers: Metastatic properties of the human prostatic cell line, PPC-1, in athymic nude mice. J Urol 145, 1088-91 (1991)
87. Silletti S., J. P. Yao, K. J. Pienta and A. Raz: Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Int J Cancer 63, 100-105 (1995)
88. Kozlowski J. M., I. J. Fidler, D. Campbell, Z. Xu, M. E. Kaighn and I. R. Hart: Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 44, 3522-9 (1984)
89. Yin L., N. Bennani-Baiti and C. T. Powell: Phorbol ester-induced apoptosis of C4-2 cells requires both a unique and a redundant protein kinase C signaling pathway. J Biol Chem 280, 5533-41 (2005)
90. van Bokhoven A., M. Varella-Garcia, C. Korch and G. J. Miller: TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 61, 6340-6344 (2001)
91. Shankar S., T. R. Singh and R. K. Srivastava: Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 61, 35-49 (2004)
92. Kaliberov S. A., L. N. Kaliberova, C. R. Stockard, W. E. Grizzle and D. J. Buchsbaum: Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. Mol Ther 10, 1059-70 (2004)
93. Liang Y., M. A. Eid, R. W. Lewis and M. V. Kumar: Mitochondria from TRAIL-resistant prostate cancer cells are capable of responding to apoptotic stimuli. Cell Signal 17, 243-51 (2005)
94. Rokhlin O. W., N. Guseva, A. Tagiyev, C. M. Knudson and M. B. Cohen: Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Oncogene 20, 2836-43 (2001)
95. Ng C. P., A. Zisman and B. Bonavida: Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 53, 286-99 (2002)
96. Ng C. P. and B. Bonavida: X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther 1, 1051-8 (2002)
97. Amantana A., C. A. London, P. L. Iversen and G. R. Devi: X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3, 699-707 (2004)
98. Lin H. K., S. Yeh, H. Y. Kang and C. Chang: Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98, 7200-7205 (2001)
99. Lin H. K., L. Wang, Y. C. Hu, S. Altuwaijri and C. Chang: Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21, 4037-4048 (2002)
100. Yeh S., H. Lin, H. Kang, T. H. Thin, M. Lin and C. Chang: From HER2/Neu signal cascade to androgen receptor and its target coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96, 5458-5463 (1999)
101. Nazareth L. V. and N. L. Weigel: Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271, 19900-19907 (1996)
102. Yang L., S. Xie, S. J. Md, S. Altuwaijri, J. Ni, E. Kim, Y. T. Chen, Y. C. Hu, L. Wang, K. H. Chuang, C. T. Wu and C. Chang: Induction of androgen receptor expression by PI3K/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem (2005)
103. Chang C. J., D. J. Freeman, H. Wu: PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem 279, 29841-8 (2004)
104. Cory S. and J. M. Adams: The bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer, 2, 647-656 (2002)
105. Downward J.: PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15, 177-82 (2004)
106. Downward J.: How BAD phosphorylation is good for survival. Nat Cell Biol 1, E33-5 (1999)
107. Cardone M. H., N. Roy, H. R. Stennicke, G. S. Salvesen, T. F. Franke, E. Stanbridge, S. Frisch and J. C. Reed: Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318-21 (1998)
108. Suh J. and A. B. Rabson: NF-kappaB activation in human prostate cancer important mediator or epiphenomenon? J Cell Biochem 91, 100-17 (2004)
109. Wang C. Y., M. W. Mayo, R. G. Komeluk, D. V. Goeddel and A. S. Baldwin: NF-kB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683, (1998)
110. Catz S. D. and J. L. Johnson: Transcriptional regulation of Bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20, 7342-7351 (2001)
111. Wang G., E. Reed and Q. Q. Li: Apoptosis in prostate cancer Progressive and therapeutic implications. Int J Mol Med 14, 23-34, (2004)
112. Yamamoto Y., M. J. Yin and R. B. Gaynor: IkappaB kinase alpha (IKKalpha) regulation of IKKbeta kinase activity. Mol Cell Biol 20, 3655-66 (2000)
113. Gustin J. A., T. Maehama, J. E. Dixon and D. B. Donner. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol Chem 276, 27740-4 (2001)
114. Baeuerle P. A., D. Baltimore D: NF-kappa B: ten years after. Cell 87, 13-20 (1996)
115. Yuan X. J. and Y. E. Whang: PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21, 319-27 (2002)
116. Sonnemann J., V. Gekeler, A. Sagrauske, C. Muller, H. P. Hofmann and J. F. Beck: Down-regulation of protein kinase Ceta potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells. Mol Cancer Ther 3, 773-81 (2004)
117. Holen I., P. I. Croucher, F. C. Hamdy and C. L. Eaton: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62, 1619-23 (2002)
118. Nyambo R., N. Cross, J. Lippitt, I. Holen, G. Bryden, F. C. Hamdy and C. L. Eaton: Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 19, 1712-21 (2004)
119. Rokhlin O. W., A. F. Taghiyev, N. V. Guseva, R. A. Glover, S. I. Syrbu and M. B. Cohen: TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther 1, 631-7 (2002)
120. Adler V. V., A. V. Polotskaia, E. S. Gershtein and M. A. Krasil'nikov: Signaling pathways that control the growth and survival of prostate tumor cells in the absence of androgens. Mol Biol (Mosk) 37, 688-95 (2003)
121. Rokhlin O. W., A. F. Taghiyev, N. V. Guseva, R. A. Glover, P. M. Chumakov, J. E. Kravchenko and M. B. Cohen: Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene Jun 20 (2005)
122. Liao X., L. Zhang, J. B. Thrasher, J. Du, B. Li: Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2, 1215-22 (2003)
123. Sah N. K., A. Munshi, J.F., Kurland, T. J. McDonnell, B. Su and R. E. Meyn: Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 278, 20593-602 (2003)
124. Hortobagyi G. N.: Anthracyclines in the treatment of cancer. An overview. Drugs 54, 1-7 (1997)
125. Kang J., J. Bu, Y. Hao and F. Chen: Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis May 17 (2005)
126. Kelly M. M., B. D. Hoel and C. Voelkel-Johnson: Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 1, 520-7 (2002)
127. Munshi A., T. J. McDonnell and R. E. Meyn: Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 50, 46-52 (2002)
128. Wu X.X., Y. Kakehi, Y. Mizutani, T. Kamoto, H. Kinoshita, Y. Isogawa, T. Terachi and O. Ogawa: Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 20, 949-54 (2002)
129. El-Zawahry A., J. McKillop and C. Voelkel-Johnson: Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 5, 2 (2005)
130. Kufe D. W., R. E. Pollock, R. R. Weichselbaum, R. C. Bast Jr., T. S. Gansler, J. F. Holland and E. Frei III: Chemotherapeutic Agents. In: Cancer Medicine. BC Decker Inc, Hamilton (Canada) (2003)
131. Zisman A., C.P. Ng, A.J. Pantuck, B. Bonavida and A. S. Belldegrun: Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother 24, 459-71 (2001)
132. Griffith T. S. and T. J. Kemp: The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother Pharmacol 52, 175-84 (2003)
133. Malathi K., J. M. Paranjape, R. Ganapathi and R. H. Silverman: HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2′,5′-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 64, 9144-51 (2004)
134. Kim K. M. and Y. J. Lee: Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene 24, 355-66 (2005)
135. Nikrad M., T. Johnson, H. Puthalalath, L. Coultas, J. Adams and A. S. Kraft: The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 4, 443-9 (2005)
136. Lashinger L. M., K. Zhu, S. A. Williams, M. Shrader, C. P. Dinney and D. J. McConkey: Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65(11), 4902-8 (2005)
137. Johnson T. R., K. Stone, M. Nikrad, T. Yeh, W. X. Zong, C. B. Thompson, A. Nesterov and A.S. Kraft: The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22, 4953-63 (2003)
138. Eid M. A., R. W. Lewis and M. V. Kumar: Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). Mol Cancer Ther 1, 831-40 (2002)
139. Sridhar S., A. A. Ali, Y. Liang, M. F. El Etreby, R. W. Lewis and M. V. Kumar: Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res 61, 7179-83 (2001)
140. Almasan A.: Cellular commitment to radiation-induced apoptosis. Radiat Res 153, 347-50 (2000)
141. Hamasu T., O. Inanami, T. Asanuma and M. Kuwabara: Enhanced induction of apoptosis by combined treatment of human carcinoma cells with X rays and death receptor agonists. J Radiat Res (Tokyo) 46, 103-10 (2005)
142. Wendt J., C. von Haefen, P. Hemmati, C. Belka, B. Dorken and P. T. Daniel: TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 24, 4052-64 (2005)
143. Seol J. W., Y. J. Lee, H. S. Kang, I. S. Kim, N. S. Kim, Y. G. Kwak, T. H. Kim, D. W. Seol and S. Y. Park: Wortmannin elevates Tumor Necrosis Factor-Related Apoptosis-inducing Ligand sensitivity in LNCaP cells through down-regulation of IAP-2 protein. Exp Oncol 27, 120-4 (2005)
144. Barnett S. F., D. Defeo-Jones, S. Fu, P. J. Hancock, K. M. Haskell, R. E. Jones, J. A. Kahana, A. M. Kral, K. Leander, L. L. Lee, J. Malinowski, E. M. McAvoy, D. D. Nahas, R. G. Robinson and H. E. Huber: Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385, 399-408 (2005)
145. Wang A. H., N. R. Bertos, M. Vezmar, N. Pelletier, M. Crosato, H. H. Heng, J. Th'ng, J. Han and X. J. Yang: HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol 19, 7816-27 (1999)
146. Grozinger C. M., C. A. Hassig and S. L. Schreiber: Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A 96, 4868-73 (1999)
147. Vanoosten R. L., J. M. Moore, A. T. Ludwig and T. S. Griffith: Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11, 542-52 (2005)
148. Sonnemann J., J. Gange, K. S. Kumar, C. Muller, P. Bader and J. F. Beck: Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 23, 99-109 (2005)
149. Taghiyev A.F., N.V. Guseva, M.T. Sturm, O.W. Rokhlin and M.B. Cohen: Trichostatin A (TSA) Sensitizes the Human Prostatic Cancer Cell Line DU145 to Death Receptor Ligands Treatment. Cancer Biol Ther 4 (2005)
150. Rokhlin O. W., R. A. Glover, A.F. Taghiyev, N. V. Guseva, R. E. Seftor, I. Shyshynova, A. V. Gudkov and M. B. Cohen: Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription. J Biol Chem 277, 33213-9 (2002)
151. Sun S. Y., P. Yue and R. Lotan: Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 19, 4513-22 (2000)
152. Lee Y. J., M.S. Moon, S.J. Kwon and J.G. Rhee: Hypoxia and low glucose differentially augments TRAIL-induced apoptotic death. Mol Cell Biochem 270, 89-97 (2005)
153. Jeon K. I., J. K. Rih, H. J. Kim, Y. L. Lee, C. H. Cho, I. D. Goldberg, E. M. Rosen and I. Bae: Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett 544(1-3), 246-51 (2003)
154. Kim Y., N. Suh, M. Sporn and J.C. Reed: An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 277, 22320-9 (2002)
155. Lee Y. J., J. J. Song, J.H. Kim, H.R. Kim and Y.K. Song: Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway. Exp Cell Res 293(1), 129-43 (2004)
156. Nam S. Y., A. A. Amoscato and Y. L. Lee: Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene 21, 337-46 (2002)
157. Yamaguchi K., R. G. Uzzo, J. Pimkina, P. Makhov, K. Golovine, P. Crispen and V. M. Kolenko: Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene May 16 (2005)
158. Huerta-Yepez S., M. Vega, A. Jazirehi, H. Garban, F. Hongo, G. Cheng, B. Bonavida: Nitric oxided sensitizes prostate carcinoma cell lines to TRAIL-inducecd apoptosis via inactivation of NF-kappaB and inhibition of Bcl-xL expression. Oncogene 23, 4993-5003 (2004)
159. Hod Y.: Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J Cell Biochem 92, 1221-33 (2004)
160. Landis S. H., T. Murray, S. Bolden and P. A. Wingo: Cancer statistics. CA Cancer J Clin 49, 8-31 (1999)
161. Johnstone R.W., A.A. Ruefli and S.W. Lowe: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-64 (2002)
162. Ruffion A., K. A. Al-Sakkaf, B. L. Brown, C. L. Eaton, F. C. Hamdy and P. R. Dobson: The survival effect of prolactin on PC3 prostate cancer cells. Eur Urol 43, 301-8 (2003)